vs
Side-by-side financial comparison of Scienture Holdings, Inc. (SCNX) and Alaunos Therapeutics, Inc. (TCRT). Click either name above to swap in a different company.
Over the past eight quarters, Alaunos Therapeutics, Inc.'s revenue compounded faster (NaN% CAGR vs NaN%).
Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel T cell receptor (TCR) immunotherapies for the treatment of hard-to-treat solid tumors. The firm focuses on advancing precision oncology candidates targeting shared tumor antigens, serving global oncology patient populations via internal R&D and cross-sector partnerships.
SCNX vs TCRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $-168.7K | $3.0K |
| Net Profit | $-28.1M | — |
| Gross Margin | 144.5% | — |
| Operating Margin | 17487.0% | — |
| Net Margin | 16668.9% | — |
| Revenue YoY | — | -40.0% |
| Net Profit YoY | -292.6% | -20.5% |
| EPS (diluted) | $-1.70 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $-168.7K | $3.0K | ||
| Q3 25 | $590.0K | $0 | ||
| Q2 25 | $0 | $0 | ||
| Q1 25 | $10.3K | $2.0K | ||
| Q4 24 | — | $5.0K | ||
| Q3 24 | $64.9K | $0 | ||
| Q2 24 | $18.7K | $4.0K | ||
| Q1 24 | — | $1.0K |
| Q4 25 | $-28.1M | — | ||
| Q3 25 | $-3.6M | $-1.2M | ||
| Q2 25 | $-6.7M | $-1.1M | ||
| Q1 25 | $-3.1M | $-1.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-3.2M | $-1.1M | ||
| Q2 24 | $-1.8M | $-1.1M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | 144.5% | — | ||
| Q3 25 | 97.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 6.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 17487.0% | — | ||
| Q3 25 | -739.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -34814.9% | -54600.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -5392.7% | — | ||
| Q2 24 | -7998.8% | -29150.0% | ||
| Q1 24 | — | -174200.0% |
| Q4 25 | 16668.9% | — | ||
| Q3 25 | -611.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -29869.3% | -53650.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -4908.3% | — | ||
| Q2 24 | -9807.5% | -28225.0% | ||
| Q1 24 | — | -168200.0% |
| Q4 25 | $-1.70 | — | ||
| Q3 25 | $-0.19 | $-0.55 | ||
| Q2 25 | $-0.48 | $-0.63 | ||
| Q1 25 | $-0.33 | $-0.67 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.34 | $-0.70 | ||
| Q2 24 | $-1.30 | $-0.71 | ||
| Q1 24 | — | $-1.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.7M | $1.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $70.1M | $2.2M |
| Total Assets | $84.2M | $3.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.7M | $1.4M | ||
| Q3 25 | — | $1.9M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $319.0K | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | — | $4.1M |
| Q4 25 | — | — | ||
| Q3 25 | $2.0M | — | ||
| Q2 25 | $3.6M | — | ||
| Q1 25 | $3.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $70.1M | $2.2M | ||
| Q3 25 | $82.7M | $2.8M | ||
| Q2 25 | $77.9M | $3.7M | ||
| Q1 25 | $81.2M | $1.1M | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | $85.1M | $2.7M | ||
| Q2 24 | $11.8M | $3.8M | ||
| Q1 24 | — | $4.8M |
| Q4 25 | $84.2M | $3.0M | ||
| Q3 25 | $104.8M | $3.7M | ||
| Q2 25 | $104.3M | $4.7M | ||
| Q1 25 | $106.4M | $2.1M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | $94.3M | $3.5M | ||
| Q2 24 | $14.8M | $4.7M | ||
| Q1 24 | — | $6.0M |
| Q4 25 | — | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.2M | $-2.9M |
| Free Cash FlowOCF − Capex | — | $-3.0M |
| FCF MarginFCF / Revenue | — | -98900.0% |
| Capex IntensityCapex / Revenue | — | 3266.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.2M | $-2.9M | ||
| Q3 25 | $-3.2M | $-844.0K | ||
| Q2 25 | $-2.0M | $-701.0K | ||
| Q1 25 | $-3.0M | $-772.0K | ||
| Q4 24 | — | $-5.0M | ||
| Q3 24 | $-5.4M | $-781.0K | ||
| Q2 24 | $4.2M | $-1.7M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | $-3.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-5.4M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -98900.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -8325.7% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 3266.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 18.5% | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
